HomeIMGN • BMV
add
ImmunoGen Ord Shs
Previous close
$268.50
Year range
$268.50 - $268.50
Market cap
8.72B USD
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2023info | Y/Y change |
|---|---|---|
Revenue | 113.42M | 637.72% |
Operating expense | 37.74M | 12.26% |
Net income | 30.75M | 139.54% |
Net profit margin | 27.11 | 105.36% |
Earnings per share | 0.10 | 132.26% |
EBITDA | 26.38M | 134.26% |
Effective tax rate | -3.94% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 605.54M | 95.64% |
Total assets | 822.10M | 129.13% |
Total liabilities | 260.50M | 44.09% |
Total equity | 561.60M | — |
Shares outstanding | 266.26M | — |
Price to book | 127.25 | — |
Return on assets | 8.45% | — |
Return on capital | 10.17% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2023info | Y/Y change |
|---|---|---|
Net income | 30.75M | 139.54% |
Cash from operations | 2.77M | 104.31% |
Cash from investing | -1.35M | -124.92% |
Cash from financing | 32.13M | 7,056.35% |
Net change in cash | 33.55M | 152.12% |
Free cash flow | -2.32M | 91.72% |
About
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Founded
1981
Headquarters
Website
Employees
277
